Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) to Equalweight, 'HCV opportunity comes into focus, while COVID outcome remains uncertain'
Tweet Send to a Friend
(Updated - August 12, 2024 4:05 PM EDT)
Morgan Stanley analyst Matthew Harrison upgraded Atea Pharmaceuticals (NASDAQ: AVIR) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Morgan Stanley analyst Matthew Harrison upgraded Atea Pharmaceuticals (NASDAQ: AVIR) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
